AngioDynamics Inc. (NASDAQ:ANGO) Reports Narrowed Loss and Revenue Beat in Q2

AngioDynamics Posts Narrowed Loss, Tops Revenue Estimates in Q2

Medical technology firm AngioDynamics Inc (NASDAQ:ANGO) reported financial results for its fiscal 2026 second quarter, delivering a top-line beat and a significant improvement in profitability metrics compared to analyst expectations. The company's performance, driven by strong growth in its key Med Tech platforms, was met with a positive initial reaction in pre-market trading.

Earnings and Revenue Versus Estimates

For the quarter ended November 30, 2025, AngioDynamics reported net sales of $79.4 million, representing an 8.8% increase on a pro forma basis compared to the prior-year period. This figure came in ahead of the consensus analyst estimate of $77.8 million.

On the bottom line, the company reported an adjusted loss per share of $0.00. This result substantially outperformed the analyst forecast, which anticipated a loss of $0.10 per share. The GAAP net loss for the quarter was $6.4 million, or $0.15 per share.

Key financial highlights from the quarter include:

• Pro Forma Net Sales: $79.4 million (vs. estimate of $77.8 million)
• Adjusted EPS: $0.00 (vs. estimated loss of $0.10)
• Adjusted EBITDA: $5.9 million, up from $3.1 million in the prior-year quarter.
• Gross Margin: 56.4%, a 170 basis point improvement year-over-year.
• Cash Position: Ended the quarter with $41.6 million in cash and a debt-free balance sheet.

Market Reaction and Strategic Performance

The better-than-expected results, particularly the move toward breakeven on an adjusted EPS basis, appear to have resonated with investors. Shares of AngioDynamics were trading higher in pre-market activity following the announcement.

This positive sentiment is likely underpinned by the company's successful execution of its strategic transformation. Growth was led by the high-margin Med Tech segment, which saw sales increase 13.0% to $35.7 million. Within this segment, the Auryon atherectomy platform grew 18.6%, the NanoKnife oncology platform grew 22.2%, and the Mechanical Thrombectomy business (AngioVac and AlphaVac) grew 3.9%.

Updated Financial Guidance

Management raised its full-year outlook, reflecting confidence in the ongoing momentum. The updated fiscal 2026 guidance now includes:

• Net Sales: Increased to a range of $312 - $314 million (up from prior guidance of $308 - $313 million).
• Adjusted EBITDA: Increased to a range of $8.0 - $10.0 million (up from $6.0 - $10.0 million).
• Med Tech Growth: Unchanged at 14% - 16%.
• Adjusted EPS: Unchanged at a loss of ($0.33) – ($0.23).

The company's sales guidance midpoint of $313 million sits slightly below the current analyst consensus estimate of $316.4 million for the full year. For the upcoming third quarter, analysts are projecting sales of $78.4 million and an adjusted EPS loss of $0.09.

Regulatory and Pipeline Progress

The quarter was also marked by several regulatory milestones that support future growth initiatives:

• Received FDA Investigational Device Exemption (IDE) approval for the APEX-Return study evaluating the AlphaReturn Blood Management System for acute pulmonary embolism.
• Received FDA IDE approval for the PAVE clinical study evaluating the AngioVac System for right-sided infective endocarditis.
• Secured FDA 510(k) clearance for a modified AlphaVac F1885 System with expanded indications.

Leadership Transition

Alongside the earnings, the company announced that President and CEO Jim Clemmer intends to retire upon the appointment of a successor, anticipated during fiscal 2027. Clemmer will remain in his role to oversee the transition. The Board has initiated a search for the next CEO.

Conclusion

AngioDynamics' second-quarter results demonstrate tangible progress in its shift toward a higher-growth, more profitable Med Tech portfolio. Beating both revenue and earnings estimates, while raising its full-year EBITDA guidance, signals strengthening operational execution. The market's initial positive reaction suggests investors are encouraged by the improved profitability trajectory and the continued clinical advancements of its flagship platforms.

For a detailed look at historical earnings, future estimates, and analyst projections for AngioDynamics, visit the earnings and estimates page.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, nor does it recommend buying or selling any securities. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.